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Abstract
Background: HAART rollout in Latin America and the Caribbean has increased from approximately 210,000 in 2003 to
390,000 patients in 2007, covering 62% (51%–70%) of eligible patients, with considerable variation among countries. No
multi-cohort study has examined rates of and reasons for change of initial HAART in this region.
Methodology: Antiretroviral-naı ¨ve patients .=18 years who started HAART between 1996 and 2007 and had at least one
follow-up visit from sites in Argentina, Brazil, Chile, Haiti, Honduras, Mexico and Peru were included. Time from HAART
initiation to change (stopping or switching any antiretrovirals) was estimated using Kaplan-Meier techniques. Cox
proportional hazards modeled the associations between change and demographics, initial regimen, baseline CD4 count,
and clinical stage.
Principal Findings: Of 5026 HIV-infected patients, 35% were female, median age at HAART initiation was 37 years
(interquartile range [IQR], 31–44), and median CD4 count was 105 cells/uL (IQR, 38–200). Estimated probabilities of
changing within 3 months and one year of HAART initiation were 16% (95% confidence interval (CI) 15–17%) and 28% (95%
CI 27–29%), respectively. Efavirenz-based regimens and no clinical AIDS at HAART initiation were associated with lower risk
of change (hazard ratio (HR)=1.7 (95% CI 1.1–2.6) and 2.1 (95% CI 1.7–2.5) comparing neverapine-based regimens and other
regimens to efavirenz, respectively; HR=1.3 (95% CI 1.1–1.5) for clinical AIDS at HAART initiation). The primary reason for
change among HAART initiators were adverse events (14%), death (5.7%) and failure (1.3%) with specific toxicities varying
among sites. After change, most patients remained in first line regimens.
Conclusions: Adverse events were the leading cause for changing initial HAART. Predictors for change due to any reason
were AIDS at baseline and the use of a non-efavirenz containing regimen. Differences between participant sites were
observed and require further investigation.
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Introduction
An estimated 1.93 million people live with HIV in Latin
America and the Caribbean, comprising 5.7% of all infected
persons worldwide; the adult prevalence in this region is 0.5%[1].
Access to antiretroviral (ARV) therapy has improved and at the
end of 2007 approximately 390,000 patients in this region were
receiving antiretroviral therapy with an overall coverage of 62%
(51%–70%), although considerable variation exists between
countries[2,3]. Unfortunately, 75% of patients still initiate
treatment at advanced stages of disease[4–8].
Treatment toxicities and adherence problems may lead to
suboptimal therapy, discontinuation, and treatment failure. Early
modification of initial highly active antiretroviral therapy
(HAART) has been associated with poor clinical outcomes[9].
Therefore, knowing why patients modify therapy could improve
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regarding initiation and management of HAART in specific
patient populations, and inform interventions to reduce HAART
discontinuation.
The frequency and reasons for HAART change have been
assessed by cohort studies from resource-rich and -limited settings,
but Latin America and the Caribbean have been largely
underrepresented in these studies[10–16]. Observational studies
from sites in Argentina, Brazil, Haiti and Peru have described the
occurrence of adverse events and durability of first regimen
[17–23]. However, no multisite study has addressed frequency and
reasons for change in this region.
The Caribbean, Central and South America Network for HIV
Research (CCASAnet) collaboration includes sites from seven
nations: Argentina, Brazil, Chile, Haiti, Honduras, Mexico, and
Peru. In an earlier study of antiretroviral-naı ¨ve subjects starting
HAART, mortality rates in the CCASAnet cohort were similar to
those reported for resource-limited settings with a 1-year
probability of death for the combined cohort of 8.3%, although
this varied considerably across sites[8]. The purpose of the current
study is to explore the frequency of, risk factors for, and reasons for
changing/discontinuing HAART during the first year after
initiation in the CCASAnet region.
Methods
Ethics Statement
This study was conducted according to the principles expressed
in the Declaration of Helsinki. Institutional Review Board
approval was obtained locally for each participating site and the
coordinating centre: Comite ´ de Bioe ´tica de Fundacio ´n Hue ´sped;
Comite ˆd eE ´tica em Pesquisa-Universidade Federal Do Rı ´oD e
Janeiro; Comite ´E ´tico-Cientı ´fico del Servicio de Salud Metropo-
litano Central, Ministerio de Salud, Gobierno de Chile; Human
Research Protections Programs, Division of Research Integrity,
Weill Cornell Medical College; Comite ´d eE ´tica en Investigacio ´n
Biome ´dica de la Unidad de Investigacio ´n Cientı ´fica, Facultad de
Ciencias Me ´dicas, Universidad Nacional Auto ´noma de Honduras;
Comite ´ Institucional de Investigacio ´n Biome ´dica en Humanos,
Instituto Nacional de Ciencias Me ´dicas y Nutricio ´n Salvador
Zubira ´n; Vicerrectorado de Investigacio ´n, Direccio ´n Universitaria
de Investigacio ´n, Ciencia y Tecnologı ´a-DUICT, Universidad
Peruana Cayetano Heredia; Institutional Review Board, Vander-
bilt University.
All data were de-identified prior to being transmitted to the
Vanderbilt Data Coordinating Centre.
In each of the countries contributing data to this study, ethical
regulations and policies permit retrospective analysis of de-
identified clinical data without informed consent when the
research is approved by an appropriately constituted ethics
committee or Institutional Review Board. These approvals were
obtained in all cases and the need to obtain informed consent was
waived by all of the ethics committees of the participating sites.
Participants and Settings
The CCASAnet cohort (www.ccasanet.vanderbilt.edu) has been
described elsewhere[24]. Briefly, the collaboration was established
in 2006 as Region 2 of the International Epidemiologic Databases
to Evaluate AIDS (IeDEA; www.iedea-hiv.org). The cohort
includes 7 sites: Fundacio ´n Hue ´sped in Buenos Aires, Argentina
(FH-Argentina); Hospital Universita ´rio Clementino Fraga Filho in
Rio de Janeiro, Brazil (HUCFF-Brazil); Fundacio ´n Arriara ´n in
Santiago, Chile (FA-Chile); Le Groupe Haı ¨tien d’Etude du
Sarcome de Kaposi et des Infections Opportunistes in Port-au-
Prince, Haiti (GHESKIO-Haiti); Instituto Honduren ˜o de Segur-
idad Social Hospital de Especialidades and Hospital Escuela in
Tegucigalpa, Honduras (IHSS/HE-Honduras); Instituto Nacional
de Ciencias Me ´dicas y Nutricio ´n Salvador Zubira ´n in Mexico
City, Mexico (INNSZ-Me ´xico); and Instituto de Medicina
Tropical Alexander Von Humboldt in Lima, Peru (IMTAvH-
Peru). Each cohort was established at a different time between
1996 and 2002 not necessarily reflecting the availability of
HAART in each country.
Data audits were performed at each site by a team from the
VDCC. The present analysis used data for the first year of follow-
up after starting HAART collected through June 2008. Included
were antiretroviral-naı ¨ve HIV-infected patients prescribed
HAART at age 18 years or older with at least one follow-up visit.
Initiation of HAART at each site followed either national or
World Health Organization guidelines[25–30]. Guidelines from
Argentina, Brazil, Chile, Honduras and Mexico recommend drug
substitutions after toxicity and switching regimens after virologic
failure[25,27–29]. In contrast, in Haiti and Peru failure was
defined according to WHO clinical and immunologic criteria[30].
Table 1 lists site-specific practices related to initiation criteria,
laboratory monitoring, and regimen availability.
Outcomes
The primary outcome was first change of regimen during the
first year of HAART. Regimen change was defined as any
alteration–switch or discontinuation–of $1 antiretroviral. Discon-
tinuation was defined as simultaneous stopping of all antiretrovi-
rals without initiation of a subsequent regimen for more than 30
days. Dosage adjustments and interruptions of therapy shorter
than 30 days were ignored because of inconsistent recording of
short interruptions across sites. Reasons for change were collected
by each site and classified at the coordinating centre. Specific
definitions of reasons for regimen change, including definition of
treatment failure, were not standardized across sites and only
included if they prompted a regimen change. Secondary analyses
classified patients who died or were lost to follow-up (LTFU) while
on their first HAART as having discontinued treatment. Patients
without a visit for 6 months were classified as LTFU. The 6-month
interval was chosen to include the longest interval between regular
visits in participant sites, although most sites scheduled visits every
3 months.
Data Sources and Measurements
Baseline CD4 count was defined as the measurement closest to
HAART initiation but not more than 6 months prior to, or 7 days
after, the date of HAART start. Baseline HIV-1 plasma viral load
(PVL) was defined as the pre-HAART measurement closest to, but
not more than 6 months prior to, HAART initiation. Baseline
weight and hemoglobin were defined as the measurements closest
to HAART initiation within +/2 30 days. HAART was defined as
protease inhibitor (PI)-based (1 ritonavir-boosted or unboosted PI
plus $2 nucleoside reverse-transcriptase inhibitors [NRTI]), non-
nucleoside reverse transcriptase (NNRTI)-based (1 NNRTI plus
$2 NRTIs), or other combinations (including triple NRTI
regimens and any other regimen containing a minimum of three
drugs). Clinical stage of disease was defined as AIDS (WHO stage
4, CDC stage C, or 1986 CDC stage 4), non-AIDS, or unknown.
Statistical Analysis
Kaplan-Meier estimates computed probabilities of change per
site. Time was measured from the start of HAART and ended at
the earliest of regimen change, discontinuation, death, last visit
before LTFU, last visit before the database closing, or 365 days.
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the most recent visit recorded in the database, and ranged from
March 2007 to June 2008. The relationship between time to
change and baseline variables was assessed using Cox proportional
hazards models applied separately for each site. The primary
multivariable analyses only included baseline predictors whose
hazard ratio could be computed for all sites. Secondary, site-
specific multivariable analyses included other routinely collected
predictors with .50% non-missing data. In multivariable analyses,
missing values of baseline predictors were accounted for using
multiple imputation techniques applied separately within each
site[31]. CD4 count and date of HAART initiation were included
in models as continuous variables and expanded using restricted
cubic splines to avoid linearity assumptions[32]. The combined
hazard ratios and 95% confidence intervals (CI) were computed
based on the results of site-specific hazard ratios using the meta-
analysis approach of DerSimonian and Laird [33], a random
effects method which makes no assumption regarding proportional
hazards across sites[34]. All analyses were performed using R
statistical software, version 2.8.1 (http://www.r-project.org).
Analysis scripts are available at http://ccasanet.vanderbilt.edu/
files/public/switch.nw
Results
A total of 5026 naı ¨ve patients starting HAART with at least one
follow-up visit were included. Patient characteristics at HAART
initiation are summarized by site in Table 2. Across all sites, 35%
were female, median age was 37 years, median CD4 count was
105 cells/mL (interquartile range [IQR]: 38, 200), 47% of subjects
had clinical AIDS, and 78% of subjects had either
CD4,200 cells/mL or clinical AIDS.
Table 2 also describes initial HAART regimen per site. The
majority started HAART between 2002–2005 although 26% of
patients from HUCFF-Brazil initiated prior to 2000. Across sites,
NNRTI-based initial regimens were most common (84%) with
efavirenz (EFV) the most frequently used (58.5%) except in
IMTAvH-Peru. Eight percent of initial regimens were ritonavir-
boosted PI-based: saquinavir (34%), lopinavir (31%) and indinavir
(26%). Unboosted PI-based regimens accounted for 5% of initial
regimens in the combined cohort; but were commonly used before
2000 in HUCFF-Brazil. Other regimens were mainly triple
NRTIs (89%). Among nucleosides, lamivudine (3TC) was included
in nearly all initial regimens (97%). Zidovudine (ZDV) was
included in nearly 80% of all initial regimens; 84% and 81% of
patients on EFV- and NVP-based regimens, respectively, were on
ZDV, compared to 70% of patients who were not started on
NNRTI-based regimens. Seventy percent of regimens which did
not contain ZDV contained d4T. Didanosine and abacavir were
used in only 4.3% and 4.6% of overall regimens, respectively, and
tenofovir was used rarely (1.7%). The most common initial
regimens were 3TC, ZDV, EFV (41.2%); 3TC, ZDV, NVP
(28.1%); 3TC, d4T, NVP (5.3%); and 3TC, d4T, EFV (4.7%).
Figure 1 shows Kaplan-Meier estimates of the probability of
changing/discontinuing regimens during the first year by site. The
estimated 3-month and 1-year probabilities of change (95% CI) for
the combined cohort were 16% (15–17%) and 28% (27–29%)
respectively (Table 3). Regimen change during the first year was
lowest at IHSS/HE-Honduras and highest at IMTAvH-Peru.
Two -hundred eighty-six patients (5.7%) died during the first year
prior to changing regimens and 149 patients (3.0%) were LTFU.
When these patients were analyzed as having discontinued
regimens, then the estimated 3-month and 1-year probabilities
of change/discontinuation were 21% (95% CI 20–22%) and 36%
(95% CI 34–37%), respectively.
Most regimen changes were simple drug substitutions followed
by other regimen changes and discontinuations.
Of 1288 living patients whose initial HAART was changed,
1147 (89%) switched to a different regimen, 104 (8%) did not start
a second regimen during the observed follow-up, and 37 (3%) re-
Table 1. Treatment Program Characteristics across Sites.
Site FH-Argentina HUCFF-Brazil FA-Chile
GHESKIO-
Haiti
IHSS/HE-
Honduras INNSZ-Mexico
IMTAvH-
Peru
Year of HAART expanded access 2000 1996 Late 2001 February 2003 July 2003 2001 May 2004
Funding source for ART MOH MOH PHS, GFATM GFATM,
PEPFAR, NIH
MOH MOHS MOH, GFATM
Patients receiving free ART (%) 100 100 80 100 100 100 100
Generic ART use (%) NRTI except TDF,
NVP, EFV, SQV,
RTV are generic
NRTIs, NVP, EFV,
SQV, RTV are
generic
NRTI except
TDF, and NVP
are generic
80 90 0 90
Guidelines used for ART
Initiation and Change
National National National WHO National National WHO
Initial HAART regimens used to
treat $95% of patients, n
2 12 19521 9 9
AE reporting Not
standardized
Not
standardized
Not
standardized
Not
standardized
Not
standardized
Not
standardized
Not
standardized
Frequency of clinical visits
At HAART initiation 2–4 weeks 2–4 weeks 2–4 weeks 2–4 weeks 2–4 weeks 3–6 weeks 1–2 weeks
On ongoing HAART 3–4 months 3–4 months 4–6 months 1 month 2-6 months 4 months 2-3 months
Use of virologic monitoring Yes Yes Yes No Yes Yes Yes
Frequency of pharmacy pick-ups 1 month 1 month 1 month 1 month 1 month 1-2 months 1 month
ART, antiretrovial therapy; ARV, antiretroviral drug; MOH, Ministry of Health; GFATM, The Global Fund to Fight AIDS, Tuberculosis and Malaria; PEPFAR, US President’s
Emergency Plan for AIDS Relief; NIH, US National Institutes of Health.
doi:10.1371/journal.pone.0010490.t001
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FH-Argentina HUCFF-Brazil FA-Chile
GHESKIO-
Haiti
IHSS/HE-
Honduras
INNSZ-
Mexico IMTAvH-Peru Combined
n=720 (14%) n=522 (10%) n=546 (11%) n=1646 (33%) n=324 (6%) n=414 (8%) n=854 (17%) n=5026
Female 209 (29%) 175 (33.5%) 69 (12.6%) 879 (53.4%) 128 (39.5%) 52 (12.6%) 253 (29.6%) 1765 (35.1%)
Age
a 36 (31, 43) 37 (32, 45) 36 (30, 42) 39 (33, 45) 37 (31, 41) 35 (29, 42) 34 (28, 40) 37 (31, 44)
Route of Infection
Heterosexual
b 249 (47.3%) 219 (62.2%) 160 (29.6%) - 323 (99.7%)
c 148 (35.7%) 583 (68.8%) 1682 (56%)
c
IVDU 66 (12.5%) 7 (2%) 2 (0.4%) - 1 (0.3%) 0 (0%) 0 (0%) 76 (2.5%)
MSM 208 (39.5%) 106 (30.1%) 378 (70%) - 0 (0%) 263 (63.5%) 264 (31.1%) 1219 (40.6%)
Other 3 (0.6%) 20 (5.7%) 0 (0%) - 0 (0%) 3 (0.7%) 1 (0.1%) 27 (0.9%)
Missing 194 (26.9%) 170 (32.6%) 6 (1.1%) 1646 (100%) 0 (0%) 0 (0%) 6 (0.7%) 2022 (40.2%)
Clinical Stage
not AIDS
b 487 (68%) 95 (26.2%) 302 (55.4%) 944 (57.4%) 186 (59.2%) 226 (56.2%) 305 (37.3%) 2545 (53%)
AIDS 229 (32%) 267 (73.8%)
d 243 (44.6%) 702 (42.6%) 128 (40.8%) 176 (43.8%) 512 (62.7%) 2257 (47%)
Missing 4 (0.4%) 160 (25.4%) 1 (0.1%) 0 (0%) 10 (2.3%) 12 (2.1%) 37 (2.8%) 224 (4.7%)
CD4 (cells/mL)
a 155 (52, 245) 153 (53, 240) 116 (32, 193) 102 (37, 192) 105 (55, 185) 88 (33, 193) 79 (32, 164) 105 (38, 200)
,50
b 150 (24.2%) 80 (24.1%) 142 (32.3%) 434 (30.4%) 49 (19.1%) 136 (34.3%) 254 (36.9%) 1245 (29.9%)
50-99 85 (13.7%) 51 (15.4%) 65 (14.8%) 258 (18.1%) 75 (29.3%) 74 (18.7%) 145 (21.1%) 753 (18.1%)
100-199 163 (26.2%) 78 (23.5%) 133 (30.3%) 407 (28.5%) 77 (30.1%) 95 (24%) 165 (24%) 1118 (26.9%)
200-349 156 (25.1%) 102 (30.7%) 91 (20.7%) 283 (19.8%) 47 (18.4%) 84 (21.2%) 99 (14.4%) 862 (20.7%)
$350 67 (10.8%) 21 (6.3%) 8 (1.8%) 47 (3.3%) 8 (3.1%) 7 (1.8%) 25 (3.6%) 183 (4.4%)
Missing
e 99 (13.8%) 190 (36.4%) 107 (19.6%) 217 (13.2%) 68 (21%) 18 (4.3%) 166 (19.4%) 865 (17.2%)
CD4,200 or AIDS
No
b 255 (35.5%) 116 (25.1%) 96 (17.6%) 360 (21.9%) 72 (22.8%) 74 (17.9%) 127 (15.1%) 1100 (22.2%)
Yes 463 (64.5%) 347 (74.9%) 449 (82.4%) 1286 (78.1%) 244 (77.2%) 339 (82.1%) 716 (84.9%) 3844 (77.8%)
Missing 2 (0.3%) 59 (11.3%) 1 (0.2%) 0 (0%) 8 (2.5%) 1 (0.2%) 11 (1.3%) 82 (1.6%)
HIV-1 RNA (log10)
a 5 (4.5, 5.4) 4.7 (3.6, 5.2) 5.1 (4.7, 5.5) - 5 (4.7, 5) 4.9 (4.9, 4.9) 5.2 (4.7, 5.5) 5 (4.6, 5.4)
,10,000
b 13 (2.6%) 8 (5.3%) 1 (0.3%) - 2 (2.2%) 0 (0%) 33 (6.8%) 57 (2.9%)
10,000-99,999 20 (4%) 23 (15.2%) 1 (0.3%) - 4 (4.3%) 3 (0.8%) 0 (0%) 51 (2.6%)
$100,000 470 (93.4%) 120 (79.5%) 383 (99.5%) - 87 (93.5%) 353 (99.2%) 451 (93.2%) 1864 (94.5%)
Missing 217 (30.1%) 371 (71.1%) 161 (29.5%) 1646 (100%) 231 (71.3%) 58 (14%) 370 (43.3%) 3054 (60.8%)
Weight (kg)
a 66 (60, 74) 65 (58, 74) 64 (56, 72) 53 (47, 60) 59 (51, 65) 61 (53, 71) 57 (50, 64) 56 (49, 64)
Missing 647 (89.9%) 399 (76.4%) 325 (59.5%) 92 (5.6%) 94 (29%) 105 (25.4%) 212 (24.8%) 1874 (37.3%)
Hemoglobin (g/dL)
a 13.8 (11.8, 14.6) 11.7 (10, 13.7) 12.3 (10.7, 13.7) 10 (9, 11) 12.3 (10.8, 13.5) 14.2 (11.8, 15.7) 11.3 (10.3, 12.7) 11 (9.9, 13)
Missing 697 (96.8%) 267 (51.1%) 343 (62.8%) 528 (32.1%) 143 (44.1%) 165 (39.9%) 683 (80%) 2826 (56.2%)
Calendar Year
1996-1999 6 (0.8%) 136 (26.1%) 0 (0%) 0 (0%) 3 (0.9%) 0 (0%) 5 (0.6%) 150 (3%)
2000-2001 42 (5.8%) 124 (23.8%) 35 (6.4%) 0 (0%) 5 (1.5%) 3 (0.7%) 11 (1.3%) 220 (4.4%)
2002-2003 210 (29.2%) 118 (22.6%) 290 (53.1%) 699 (42.5%) 104 (32.1%) 147 (35.5%) 50 (5.9%) 1618 (32.2%)
2004-2005 325 (45.1%) 80 (15.3%) 221 (40.5%) 923 (56.1%) 100 (30.9%) 161 (38.9%) 520 (60.9%) 2330 (46.4%)
2006-2007 137 (19%) 64 (12.3%) 0 (0%) 24 (1.5%) 112 (34.6%) 103 (24.9%) 268 (31.4%) 708 (14.1%)
Initial Regimen
NNRTI 469 (65.1%) 288 (55.2%) 510 (93.4%) 1569 (95.3%) 311 (96%) 287 (69.3%) 788 (92.3%) 4222 (84%)
EFV-based 316 (67.4%) 238 (82.6%) 326 (63.9%) 922 (58.8%) 220 (70.7%) 271 (94.4%) 176 (22.3%) 2469 (58.5%)
NVP-based 153 (32.6%) 50 (17.4%) 184 (36.1%) 647 (41.2%) 91 (29.3%) 16 (5.6%) 612 (77.7%) 1753 (41.5%)
PI 21 (2.9%) 167 (32%) 23 (4.2%) 15 (0.9%) 10 (3.1%) 16 (3.9%) 21 (2.5%) 273 (5.4%)
Boosted PI 188 (26.1%) 43 (8.2%) 4 (0.7%) 7 (0.4%) 2 (0.6%) 106 (25.6%) 36 (4.2%) 386 (7.7%)
Other 42 (5.8%) 24 (4.6%) 9 (1.6%) 55 (3.3%) 1 (0.3%) 5 (1.2%) 9 (1.1%) 145 (2.9%)
ZDV Containing 542 (75.3%) 422 (80.8%) 432 (79.1%) 1515 (92%) 229 (70.7%) 289 (69.8%) 631 (73.9%) 4060 (80.8%)
Most Common Regimens
3TC,ZDV,EFV 249 (34.6%) 196 (37.5%) 237 (43.4%) 855 (51.9%) 218 (67.3%) 194 (46.9%) 121 (14.2%) 2070 (41.2%)
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those patients who re-started the same regimen during the first
year, the median time of interruption was 78 days. For those who
switched to a different regimen, the vast majority (83%) started
within a week of initial HAART discontinuation and 90% within a
month. Among those who started a second regimen while in
follow-up, 74% were NNRTI-based and 5% were first line PI-
based. Of 1013 living patients who stopped their initial ZDV-
containing regimen, 487 had a second regimen containing ZDV,
452 had a second regimen not containing ZDV, and 74 did not
start a second regimen. Table 4 details second regimens started
within 30 days of changing initial regimen.
Clinical AIDS at HAART initiation and non-efavirenz based
regimens were associated with a higher hazard of change in
unadjusted analyses for most sites and in the combined cohort
(data not shown). Multivariable analyses for each site and pooled
across sites are given in Table 5. After adjusting for sex, age,
baseline CD4 count, year of HAART initiation, and type of
regimen, the hazard of change was 1.3 times higher for a person
with clinical AIDS prior to HAART initiation than a person
without (95% CI: 1.1 to 1.5) (Table 3). Using EFV-based regimens
as the reference category, the hazard ratios for change for NVP-
based regimens and non-NNRTI-based regimens were 1.7 (95%
CI: 1.1 to 2.6) and 2.1 (95% CI: 1.7 to 2.5) respectively. The
increased hazard for change for NVP was not observed in FA-
Chile and GHESKIO-Haiti whereas it was especially pronounced
in IMTAvH-Peru. Except at GHESKIO-Haiti, patients who
started 3TC,ZDV,EFV generally had lower rates of change than
those starting other regimens (Table S1, online supplemental
material). Overall and by site there were no consistent associations
between gender, age, CD4, year of HAART initiation, or ZDV-
containing regimens and change. Results were similar when those
who died and those who died or were lost to follow-up were
assumed to have discontinued regimens (Tables S2-S3, online
supplemental material).
Multivariable analyses including HIV-1 RNA, hemoglobin,
weight, and more refined regimen categories were performed for
sites with sufficient data and are shown in Table S4 in the online
supplemental material. Higher baseline weight was associated
with a lower risk of changing regimens at IMTAvH-Peru. Higher
baseline hemoglobin was predictive of a decreased risk of
changing regimens at GHESKIO-Haiti. Patients treated with
d4T had lower hemoglobin at baseline (medians of 9.7 vs.
11.0 mg/dl, p,0.0001). Higher baseline HIV-1 RNA was
predictive of changing regimens at FA-Chile, but was not an
independent predictor at FH-Argentina, INNSZ-Mexico, or
IMTAvH-Peru.
The reported reasons for change during the first year are given
in Table 6. Adverse events (AE) prompted change in 14.4% of
HAART initiators, and were the most common reason for six of
the seven sites. Other reasons for change were failure (1.3%), the
availability of a better regimen or simplification (1.5%), drug
supply problems (1.8%), and abandonment/adherence failures
(1.1%). Of the patients who initiated HAART, 2.9% changed
regimens for an undocumented reason.
The most common AE were hematological toxicity (6.7%), skin
rash (3%) and gastrointestinal intolerance (1.9%), with substantial
heterogeneity between sites. Of HAART initiators in IHSS/HE-
Honduras, 3.7% changed regimens during the first year due to
hematological adverse events, compared to 15.8% in IMTAvH-
Peru. Among those with hematological adverse events, 73% were
anemia, 4%. The distribution of HAART initiators changing due
FH-Argentina HUCFF-Brazil FA-Chile
GHESKIO-
Haiti
IHSS/HE-
Honduras
INNSZ-
Mexico IMTAvH-Peru Combined
n=720 (14%) n=522 (10%) n=546 (11%) n=1646 (33%) n=324 (6%) n=414 (8%) n=854 (17%) n=5026
3TC,ZDV,NVP 130 (18.1%) 37 (7.1%) 167 (30.6%) 593 (36%) 1 (0.3%) 9 (2.2%) 475 (55.6%) 1412 (28.1%)
3TC,D4T,NVP 19 (2.6%) 6 (1.1%) 6 (1.1%) 49 (3%) 90 (27.8%) 2 (0.5%) 95 (11.1%) 267 (5.3%)
3TC,D4T,EFV 51 (7.1%) 29 (5.6%) 55 (10.1%) 55 (3.3%) 0 (0%) 21 (5.1%) 23 (2.7%) 234 (4.7%)
3TC,ABC,ZDV 32 (4.4%) 22 (4.2%) 8 (1.5%) 55 (3.3%) 0 (0%) 4 (1%) 2 (0.2%) 123 (2.4%)
aContinuous variables are reported as medians (interquartile range).
bPercentages are computed using the number of patients with a non-missing value.
cIHSS/HE-Honduras did not differentiate between heterosexual and MSM routes of infection. All are listed here as heterosexual.
dHUCFF-Brazil classified most patients with CD4,200 as having clinical AIDS.
eSites may have high percentages of missing CD4, HIV-1 RNA, weight, and hemoglobin values because data were not collected within the specified time frames to
count as baseline measurements (see Methods: Data Sources and Measurements).
doi:10.1371/journal.pone.0010490.t002
Table 2. Cont.
Figure 1. Probability of regimen change by site.
doi:10.1371/journal.pone.0010490.g001
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IMTAvH-Peru reporting 4.0%, 7.3%, and 5.5%, respectively,
and other sites reporting ,2%.
Within the first 3 months, AE were also the most common
reported reason for changing regimens. Ten percent of patients
changed regimens due to adverse events: 4.7% due to hemato-
logical toxicity and 2.8% due to skin rash. Forty-two patients from
GHESKIO-Haiti who were on 3TC,ABC,ZDV switched to
3TC,ZDV,EFV in April/May of 2003 because this regimen
became available and was deemed superior; each of these 42
patients had been on their initial regimen for less than 3 months.
For all NNRTI, boosted PI, and unboosted-PI-based regimens,
AE were the main reason for change, although type of AE varied
according to class. The most common AE for efavirenz-based
regimens were hematological (5.7%), central nervous system
(2.2%), and skin (1.6%); for nevirapine-based regimens: hemato-
logical (9.7%), skin (5.8%), liver (0.7%), and gastrointestinal
intolerance (0.7%); for boosted PI-based regimens: gastrointestinal
Table 3. Number of Events and Estimated Rates of Changing Regimens (95% Confidence Intervals).
FH-
Argentina
HUCFF-
Brazil FA-Chile
GHESKIO-
Haiti
IHSS/HE-
Honduras
INNSZ-
Mexico
IMTAvH-
Peru Combined
(n=720) (n=522) (n=546) (n=1646) (n=324) (n=414) (n=854) (n=5026)
1 year Change/
Discontinuation
223 (30.9%) 151 (28.9%) 154 (28.2%) 324 (19.7%) 52 (16.0%) 77 (18.65) 307 (35.9%) 1288 (25.6%)
Single Drug Substitution 82 (11.4%) 77 (14.8%) 94 (17.2%) 294 (17.9%) 22 (6.8%) 35 (8.5%) 156 (18.3%) 760 (15.1%)
Other Regimen Change 64 (8.9%) 45 (8.6%) 11 (2.0%) 29 (1.8%) 29 (9.0%) 40 (9.7%) 70 (8.2%) 288 (5.7%)
Discontinuation 77 (10.7%) 29 (5.5%) 49 (9.0%) 1 (0.1%) 1 (0.3%) 2 (0.5%) 81 (9.5%) 240 (4.8%)
Death 6 (0.8%) 7 (1.3%) 18 (3.3%) 169 (10.3%) 30 (9.3%) 11 (2.7%) 45 (5.3%) 286 (5.7%)
Loss to Follow-up (LTFU) 52 (7.2%) 10 (1.9%) 6 (1.1%) 44 (2.7%) 1 (0.3%) 15 (3.6%) 21 (2.5%) 149 (3.0%)
Rates of Change/
Discontinuation
3 months 0.17
(0.15, 0.2)
0.16
(0.13, 0.19)
0.18
(0.15, 0.21)
0.13
(0.11, 0.14)
0.09
(0.06, 0.12)
0.08
(0.06, 0.11)
0.28
(0.25, 0.31)
0.16
(0.15, 0.17)
1 year 0.33
(0.29, 0.37)
0.3
(0.25, 0.33)
0.29
(0.25, 0.33)
0.22
(0.2, 0.24)
0.18
(0.14, 0.23)
0.21 (0.17, 0.25) 0.41
(0.37, 0.44)
0.28
(0.27, 0.29)
Including death
3 months 0.18
(0.15, 0.21)
0.17
(0.14, 0.2)
0.2
(0.17, 0.24)
0.19
(0.17, 0.21)
0.15
(0.11, 0.19)
0.09
(0.06, 0.12)
0.31
(0.28, 0.34)
0.2
(0.19, 0.21)
1 year 0.34
(0.3, 0.37)
0.31
(0.27, 0.35)
0.32
(0.28, 0.36)
0.31
(0.28, 0.33)
0.27
(0.22, 0.32)
0.24
(0.19, 0.28)
0.45
(0.41, 0.48)
0.33
(0.31, 0.34)
Including LTFU and death
3 months 0.21
(0.18, 0.24)
0.17
(0.14, 0.21)
0.21
(0.17, 0.24)
0.21
(0.19, 0.23)
0.15
(0.11, 0.19)
0.1
(0.07, 0.13)
0.32
(0.29, 0.35)
0.21
(0.2, 0.22)
1 year 0.4
(0.36, 0.44)
0.32
(0.28, 0.36)
0.33
(0.29, 0.37)
0.33
(0.31, 0.35)
0.27
(0.22, 0.32)
0.27
(0.23, 0.32)
0.47
(0.43, 0.51)
0.35
(0.34, 0.37)
doi:10.1371/journal.pone.0010490.t003
Table 4. Second Regimens started within 30 days of stopping Initial Regimen.
Initial Regimen
NNRTI-EFV
(n=2469)
NNRTI-NVP
(n=1753)
Boosted PI
(n=386)
PI
(n=273)
Other
(n=145)
Total
(n=5026)
None, Death 146 (5.9%) 118 (6.7%) 13 (3.4%) 4 (1.5%) 5 (3.4%) 286 (5.7%)
None
a 68 (2.8%) 111 (6.3%) 33 (8.5%) 18 (6.6%) 10 (6.9%) 240 (4.8%)
NNRTI-EFV 200 (8.1%) 109 (6.2%) 39 (10.1%) 12 (4.4%) 52 (35.9%) 412 (8.2%)
NNRTI-NVP 166 (6.7%) 176 (10.0%) 8 (2.1%) 11 (4%) 7 (4.8%) 368 (7.3%)
Boosted PI
b 29 (1.2%) 35 (2.0%) 34 (8.8%) 13 (4.8%) 7 (4.8%) 118 (2.3%)
Unboosted PI 30 (1.2%) 19 (1.1%) 6 (1.6%) 34 (12.5%) 2 (1.4%) 91 (1.8%)
Other 9 (0.4%) 9 (0.6%) 6 (1.6%) 3 (1.1%) 2 (1.4%) 29 (0.6%)
Non-HAART Regimen 1 (0%) 25 (1.4%) 0 (0%) 4 (1.5%) 0 (0%) 30 (0.6%)
aOf the 240 living patients who did not start a second regimen within 30 days of stopping their first regimen, 136 (56.7%) started a second regimen before the end of
follow-up.
bIn the second regimen there were 54 first generation boosted PIs (SQV, IDV, NFV, or APV) and 93 second generation boosted PIs (LPV, FPV, ATV, DRV or TPV).
doi:10.1371/journal.pone.0010490.t004
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for unboosted PI- based regimens: gastrointestinal intolerance
(7%), hematological (4.8%), and skin (1.1%).
Thirty patients died within 30 days of changing their initial
HAART regimen. Adverse events were the reported reasons for
change for 21 of these 30 patients. Most of these deaths were HIV-
related or unspecified (tuberculosis 4, Kaposi’s Sarcoma 2, wasting
syndrome 2, Mycobacterium avium complex 1, Cryptococcosis 1,
non-Hodgkin lymphoma 1, multiple opportunistic infections 1,
AIDS-related but unspecified 1,); other causes included anemia 2,
unspecified pulmonary infection 2, chronic renal failure 1,
unspecified cancer 1, pancytopenia 1, and missing cause of
death 10.
Discussion
This is the first multi-cohort study in Latin America and the
Caribbean to describe rates of and reasons for changing initial
HAART regimen. We found high rates of change early after
treatment initiation with substantial variation across sites, ranging
from 8–28% in the first 3 months and 18–41% in the first
year. These rates are similar to those reported in other
cohorts[10,12–15,35].
Also in agreement with other studies[10–14,35,36], adverse
events were the main reason for change early after HAART
initiation, with significant heterogeneity in the distribution of
adverse events across sites. Hematological adverse events, .70%
of which were anemia, were most common. This was most
frequent in IMTAvH-Peru at 67%. Previous studies from Peru
also reported anemia as a main reason for discontinuation (68%),
and associated this finding with the use of standard 600 mg ZDV
in low weight patients[21]. ZDV use was associated with an
increase risk of discontinuation in the first 120 days of therapy and
this early toxicity was associated with low baseline body weight.
The high rates of HAART change due to anemia in IMTAvH-
Peru may also be a reflection of baseline anemia and the fact that
this site closely monitors anemia and changes HAART soon after
its occurrence. The distribution of change in regimen due to skin
rash also varied, with high rates in FH-Argentina, FA-Chile and
IMTAvH-Peru and low rates elsewhere. This could be in part
related to ethnicity, although this remains controversial[37–39].
GHESKIO-Haiti, with more advanced disease at baseline, had
unexpectedly lower rates of change/discontinuation due to
adverse events than other sites. However, the rates were similar
when deaths were included as discontinuations. The availability of
alternative drugs more than the occurrence of adverse events may
explain this low rate.
As expected and previously reported[10,12], patients were more
likely to change therapy shortly after HAART initiation because of
adverse events rather than treatment failure. Failure was given as
the reason for change in 5% of changes, corresponding to 1.3% of
HAART initiators. This low rate primarily may be explained by
the short duration of follow-up.
Interruption in drug supply prompted changes in 2% of
HAART initiators per site: its importance cannot be minimized
since interruptions ,30 days were ignored. Continuous provision
Table 5. Adjusted Hazard Ratios (95% Confidence Intervals) for Regimen Change/Discontinuation in First Year.
FH-Argentina
(n=720)
HUCFF-Brazil
(n=522)
FA-Chile
(n=546)
GHESKIO-
Haiti (n=1646)
IHSS/HE-
Honduras
(n=324)
INNSZ-Mexico
(n=414)
IMTAvH-Peru
(n=854) Combined
Male 0.73 (0.55, 0.98) 1.07 (0.75, 1.52) 0.78 (0.49, 1.23) 0.76 (0.58, 0.99) 0.97 (0.55, 1.72) 0.97 (0.5, 1.92) 1.06 (0.82, 1.38) 0.89 (0.78, 1.02)
Age (per 10 years) 1.02 (0.89, 1.18) 1 (0.85, 1.17) 0.96 (0.81, 1.14) 0.93 (0.82, 1.05) 1 (0.73, 1.37) 0.88 (0.69, 1.12) 0.97 (0.86, 1.09) 0.97 (0.91, 1.03)
AIDS 1.61 (1.18, 2.2) 1.37 (0.89, 2.11) 1.18 (0.79, 1.75) 1.13 (0.89, 1.42) 0.87 (0.49, 1.57) 1.42 (0.83, 2.44) 1.26 (0.98, 1.63) 1.28 (1.14, 1.45)
CD4 count
(cells/mL)
100 vs. 50 1.13 (1.05, 1.21) 0.9 (0.82, 0.99) 1.02 (0.91, 1.14) 0.97 (0.91, 1.04) 0.98 (0.8, 1.2) 0.92 (0.78, 1.08) 0.9 (0.84, 0.97) 0.98 (0.91, 1.05)
200 vs. 50 1.33 (1.12, 1.59) 0.78 (0.62, 0.98) 1.04 (0.79, 1.39) 0.94 (0.79, 1.1) 0.94 (0.58, 1.54) 0.81 (0.55, 1.21) 0.78 (0.66, 0.93) 0.94 (0.79, 1.13)
350 vs. 50 1.6 (1.2, 2.14) 0.66 (0.45, 0.96) 1.07 (0.67, 1.71) 0.9 (0.68, 1.17) 0.91 (0.41, 2.03) 0.71 (0.37, 1.36) 0.67 (0.5, 0.89) 0.91 (0.67, 1.22)
Year of HAART
initiation
2003 (ref)
a 11111111
2004 1.06 (0.96, 1.18) 1.12 (1, 1.26) 0.99 (0.83, 1.16) 0.35 (0.27, 0.44) 0.94 (0.75, 1.18) 0.94 (0.75, 1.19) 0.99 (0.85, 1.16) 0.86 (0.67, 1.11)
2005 1.05 (0.86, 1.28) 1.28 (0.99, 1.65) 0.79 (0.49, 1.28) 0.31 (0.21, 0.44) 1.06 (0.76, 1.48) 0.82 (0.6, 1.12) 0.98 (0.77, 1.25) 0.83 (0.58, 1.19)
2006 0.99 (0.67, 1.48) 1.46 (0.96, 2.21) NA 0.29 (0.14, 0.6) 1.41 (0.85, 2.33) 0.66 (0.37, 1.19) 0.96 (0.7, 1.33) NA
Regimen class
NNRTI-EFV 11111111
NNRTI-NVP 1.56 (1.07, 2.27) 1.92 (1.09, 3.39) 1.13 (0.76, 1.66) 0.63 (0.46, 0.86) 5.92 (0.23, 150.8)
b2.57 (0.89, 7.41) 1.86 (1.29, 2.69) 1.66 (1.06, 2.62)
Non-NNRTI 2.02 (1.47, 2.77) 1.62 (1.07, 2.46) 2.9 (1.72, 4.87) 2.54 (1.78, 3.64) 1.57 (0.4, 6.06) 2.01 (1.21, 3.33) 1.5 (0.83, 2.71) 2.08 (1.74, 2.48)
ZDV Containing
N o Z D V 11111111
ZDV 1.02 (0.75, 1.39) 1.04 (0.69, 1.56) 0.7 (0.47, 1.05) 0.4 (0.29, 0.56) 5.92 (0.23, 152.2)
b1.26 (0.73, 2.17) 1.32 (0.99, 1.75) 1.14 (0.68, 1.91)
aPatients who started HAART before 2003 were included in the analysis, although we chose not to reference these earlier years in the table because at most sites there
were very few patients.
bHazard ratio estimates for ZDV and NNRTI-NVP for IHSS/HE-Honduras are erratic because of co-linearity: 219/220 patients on EFV were on ZDV, whereas 1/91 patients
on NVP were on ZDV.
doi:10.1371/journal.pone.0010490.t005
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treatment interruptions affect program effectiveness[5,21].
Consistent with previous studies, individuals who died while on
their first regimen were censored at the time of death in our
primary analyses [10,13,14]. This analysis implicitly assumes that
the frequency with which these individuals would have changed
regimens had they continued to live is similar to the frequency of
changing for those patients who remained in care. To examine the
sensitivity of results to this assumption we performed additional
analyses which categorized individuals who died while on their
first regimen as having discontinued regimens. We also performed
analyses, assuming those lost to follow-up stopped therapy. This
latter assumption seems reasonable in sites where there were few
other options for HIV care, but less reasonable for sites located in
areas with several other points of care. Characteristics at HAART
initiation of those subsequently lost to follow-up for the CCASAnet
cohort have been described elsewhere[8]. Risk factors for
changing/discontinuing first regimen were similar regardless of
how those who died or were lost were classified.
For the combined cohort, clinical AIDS prior to HAART
initiation was identified as an independent predictor for treatment
change. For FH-Argentina, in contrast to other sites, there was an
increased risk of change at higher CD4 counts. A previous report
suggested that patients with higher CD4 counts were at higher risk
of GI intolerance whereas misclassification of gastrointestinal
intolerance can occur in patients with low CD4 and associated
opportunistic diseases[40]. Comorbidities in patients with ad-
vanced disease and concurrent treatments for opportunistic
diseases may affect antiretroviral tolerance and thereby increase
risk of toxicities. Late HAART initiation was associated with
higher rates of treatment change. Approximately 50% of the
patients in the combined cohort started therapy at less than
100 CD4/mL, highlighting the urgent need for timely diagnosis
and treatment of HIV-positive patients.
Efavirenz-based regimens had the lowest hazard for change.
The increased hazard for change of NVP-based regimens was
especially pronounced in IMTAvH-Peru. This may be explained
by the use of fixed dose combinations containing ZDV and anemia
frequency. In spite of the high proportions of hematological
toxicity, the hazards of change for ZDV- and non-ZDV-
containing regimens were similar. We believe that since patients
with anemia at baseline were typically assigned to non-ZDV
Table 6. Reported reasons for changing initial HAART regimen in First Year.
FH-
Argentina
HUCFF-
Brazil FA-Chile
GHESKIO-
Haiti
IHSS/HE-
Honduras
INNSZ-
Mexico
IMTAvH-
Peru Combined
(n=720) (n=522) (n=546) (n=1646) (n=324) (n=414) (n=854) (n=5026)
Changed Regimens
(% of HAART initiators) 223 (31.0%) 151 (28.9%) 154 (28.2%) 324 (19.7%) 52 (16.0%) 77 (18.6%) 307 (35.9%) 1288 (25.6%)
Reasons for Changing
(% of HAART initiators)
Adverse Events 119 (16.5%) 79 (15.1%) 111 (20.3%) 133 (8.1%) 39 (12%) 40 (9.7%) 199 (23.3%) 720 (14.3%)
Types of Adverse Events
a
Hematology
b 31 (4.3%) 25 (4.8%) 41 (7.5%) 70 (4.3%) 12 (3.7%) 22 (5.3%) 134 (15.7%) 335 (6.7%)
Skin 29 (4%) 9 (1.7%) 40 (7.3%) 20 (1.2%) 5 (1.5%) 0 (0%) 47 (5.5%) 150 (3%)
Intolerance 46 (6.4%) 18 (3.4%) 9 (1.6%) 7 (0.4%) 7 (2.2%) 5 (1.2%) 3 (0.4%) 95 (1.9%)
Nervous System, Central 6 (0.8%) 10 (1.9%) 10 (1.8%) 23 (1.4%) 10 (3.1%) 1 (0.2%) 8 (0.9%) 68 (1.4%)
Gynecomastia/Abnormal Fat Dist. 1 (0.1%) 1 (0.2%) 0 (0%) 16 (1%) 0 (0%) 0 (0%) 2 (0.2%) 20 (0.4%)
Liver 2 (0.3%) 4 (0.8%) 2 (0.4%) 0 (0%) 0 (0%) 0 (0%) 9 (1.1%) 17 (0.3%)
Nervous System, Peripheral 3 (0.4%) 2 (0.4%) 6 (1.1%) 2 (0.1%) 0 (0%) 0 (0%) 0 (0%) 13 (0.3%)
Kidney 0 (0%) 2 (0.4%) 0 (0%) 0 (0%) 0 (0%) 8 (1.9%) 0 (0%) 10 (0.2%)
Other Adverse Events
c 2 (0.3%) 7 (1.3%) 3 (0.5%) 0 (0%) 1 (0.3%) 3 (0.7%) 1 (0.1%) 17 (0.3%)
Not Specified 2 (0.3%) 5 (1%) 1 (0.2%) 2 (0.1%) 7 (2.2%) 1 (0.2%) 0 (0%) 18 (0.4%)
Failure 5 (0.7%) 12 (2.3%) 2 (0.4%) 7 (0.4%) 0 (0%) 16 (3.9%) 22 (2.6%) 64 (1.3%)
Better Regimen Available/
Simplification 5 (0.7%) 0 (0%) 13 (2.4%) 48 (2.9%) 1 (0.3%) 9 (2.2%) 0 (0%) 76 (1.5%)
Drug Supply Problems 2 (0.3%) 3 (0.6%) 0 (0%) 73 (4.4%) 1 (0.3%) 0 (0%) 10 (1.2%) 89 (1.8%)
Abandonment/Adherence Failure 11 (1.5%) 0 (0%) 16 (2.9%) 3 (0.2%) 3 (0.9%) 2 (0.5%) 19 (2.2%) 54 (1.1%)
Pregnancy-Related 5 (0.7%) 0 (0%) 0 (0%) 21 (1.3%) 1 (0.3%) 0 (0%) 0 (0%) 27 (0.5%)
Tuberculosis-Related 1 (0.1%) 2 (0.4%) 1 (0.2%) 23 (1.4%) 0 (0%) 2 (0.5%) 12 (1.4%) 41 (0.8%)
Other Reasons for Changing 20 (2.8%) 5 (1%) 10 (1.8%) 15 (0.9%) 3 (0.9%) 1 (0.2%) 27 (3.2%) 81 (1.6%)
Unknown 55 (7.6%) 50 (9.6%) 1 (0.2%) 1 (0.1%) 4 (1.2%) 7 (1.7%) 18 (2.1%) 136 (2.7%)
aDoes not necessarily add to total number of adverse events because some patients experienced multiple events which prompted regimen change.
bAmong those with a hematological adverse event, 73.4% were associated with anemia, 3.9% were not associated with anemia, and information regarding anemia was
unspecified for the remaining 22.7%.
cIncludes lactic acidosis (5), hypersensitivity reaction (2), and metabolic/dislipidemia (1).
doi:10.1371/journal.pone.0010490.t006
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‘‘protected’’ from subsequent change due to anemia. However,
baseline anemia status was not consistently collected for all sites.
We failed to identify consistent associations between gender or
age and risk of antiretroviral change, although other studies have
found that younger age and female gender predict change[13].
After the first change, most patients remained on regimens
within the same class. The outcome of second regimens was not
assessed as it was beyond the scope of this study.
Our study had several limitations. Adverse events or regimen
failures were computed only if they prompted regimen change.
Therefore, their frequency cannot be used to estimate their
occurrence, but rather the frequency of events deemed significant
enough to prompt a regimen change. Strategies for changing
regimens varied throughout the region and have evolved over
time. Therefore, differences between sites regarding rates of
toxicities, for example, may reflect site differences in guidelines for
changing regimens or availability of alternative regimens. In
addition, these data were collected retrospectively, and differences
between sites in reasons for change and adverse events may reflect
varying levels of data capture. Results of pooled analyses should be
treated with caution given the heterogeneity seen in our cohort.
We did not consider treatment modifications or interruptions
shorter than 30 days because registration of such events varied
across sites and shorter discontinuations were less likely to have
been recorded. We recognize the potential impact of minor
interruptions on treatment outcomes, particularly using NNRTI-
based regimens; such interruptions occur frequently in real life but
generally have not been considered in other cohort studies[14,41].
Although we controlled for key variables such as CD4 count
and clinical stage, patients were not randomly assigned to their
initial regimens, so rates of change may be higher for certain
regimens due to baseline characteristics rather than the regimen
itself. However, most of the associations observed in this study are
similar to those reported elsewhere[10,12–16,35,39].
In conclusion, the high rate of change due to adverse events is
consistent with studies from other cohorts. Heterogeneity between
sites may be explained by differences in baseline characteristics at
HAART initiation, programmatic differences, demographics and
population genetics. Unfortunately, with only 7-sites, we are
unable to perform analyses to investigate the impact of site-specific
factors on regimen change. Efavirenz-based regimens were widely
used and showed a lower rate of discontinuation compared to
nevirapine or PI-based treatments.
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